Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Webcasts|May 28, 2020

Accurate Weighing of Reference Standards in a QC Laboratory

For any quantitative HPLC experiment, the accurate preparation of verified standards is necessary and reliant on accurate weighing procedures. Learn about practices to ensure accurate measurements in quality control laboratories. Live: Thursday, May 28, 2020 at 11am EDT| 8am PDT| 4pm BST| 5pm CEST On demand available after airing until May 28, 2021 Register free

Register free: http://www.biopharminternational.com/bp_w/accurate

Event Overview:

For any quantitative HPLC experiment, the accurate preparation of verified standards is necessary and reliant on accurate weighing procedures. This webcast will explain practices to ensure accurate measurements including: 

  • Understand the accuracy requirements of an assay

  • Reference standard requirements

  • Laboratory balance requirements

  • Weighing techniques

  • Good manufacturing practices for quality control laboratories 

Key Learning Objectives:

  • Understand techniques essential to accurate weighing of reference standards

  • Review the importance of installation qualification, operational qualification, and performance qualification of instruments 

  • Understand the important features of laboratory balances

Speaker: Richard Forsyth, Principal Consultant, Forsyth Pharmaceutical Consulting

Time and Date: Thursday, May 28, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST 

On demand available after airing until May 28, 2021

Sponsor: Sartorius

Register free: http://www.biopharminternational.com/bp_w/accurate


Related to this article

The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.
Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.